Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
2021 · Cancers · 288 citations
https://doi.org/10.3390/cancers13061383
F
Fabio Conforti
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
171
Papers
3.8K
Citations
26
h-index
59
i10-index
Fabio Conforti is an academic researcher from Humanitas University. The author has contributed to research in topics: Myasthenia Gravis and Thymoma & Cancer Immunotherapy and Biomarkers & Immune Cell Function and Interaction. The author has an h-index of 26, co-authored 146 publications.
ORCID: 0000-0002-6233-0502Papers by this author
worksAndrogen receptor blockade promotes response to BRAF/MEK-targeted therapy
2022 · Nature · 129 citations
https://doi.org/10.1038/s41586-022-04833-8
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials
2021 · ESMO Open · 79 citations
https://doi.org/10.1016/j.esmoop.2021.100251
Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study
2018 · Journal of Pain and Symptom Management · 45 citations
https://doi.org/10.1016/j.jpainsymman.2018.03.008
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM)
2021 · ESMO Open · 22 citations
https://doi.org/10.1016/j.esmoop.2021.100188
Sex hormones, the anticancer immune response, and therapeutic opportunities
2025 · Cancer Cell · 22 citations
https://doi.org/10.1016/j.ccell.2025.02.013
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat